arcangela valle

Professional inspired by people , science, access to healthcare and lifelong learning !! 

Broad and solid seasoned executive of more than 20 years in the Pharmaceutical business skilled in Medical,

Marketing, Access, B&D and Commercial Strategy. Strong background in several therapeutic areas, such as

Oncology & Hematology , Immunology , Cardiometabolic, Neurology, Pain&Inflammation, Infectious Diseases, Dermatology, Respiratory, Aesthetics products and lately in Rare Diseases. Experience managing a matrix organization, and being part of Executive Committees. Besides, profound knowledge and records related with local and regional market, public and private payers, financial indicators, project management. Working on region and global cross-functional teams. Recognize for strong leadership profile and experience in the Biopharma ecosystem that has delivered excellent results and for identifying ways to streamline procedures. Direct and inspire team. Use the culture of excellence for improve patient value through innovative projects and programs. Enjoys challenges and thrives in  a strategic and operational level.

TEVA PHARMACEUTICALS São Paulo, Brasil                                                                       Oct´22  - Mar´25

Senior Medical Director

Lead company's medical-scientific area, being one of the strategic drivers for the business in partnership and actively collaborating with the strategic product marketing plan of all the companies in the 3 very stablished BU: Rare Disease , Oncology & Hematology and CNS being the strategic pillar responsible for the interface between internal stakeholders and the various external stakeholders ensuring compliance; Identify and promote strategic partnerships with influencers, key scientific and technical decision makers to generate new sources of value for the patient not only as the center of everything we do but also as a co-creator of what we do. Also, acting through, but not exclusively generating and strengthening the relationship with the national and international scientific medical community; Ensure the ideal alignment between medical activities and the priorities of the Multifunctional Therapeutic Teams (CVT) and other internal teams. Ensure communication and alignment with the leaders of each cross-functional team; Collaborate with potential launches by the Licensing & Portfolio.  Collaborate with the regulatory area in the evaluation of dossiers, technical evaluation of new partnerships. Support the legal area by issuing technical opinions; Be a driver and partnership with access area  / team developing strategies and answering unmet needs that will support products incorporation in the public and private market. Be responsible to support of generation of scientific evidencerelated with disease and products. Provides expertise to global stakeholders within area of responsibility. Be aligned and apply the inputs of the global Medical Affairs strategy. Be responsible to identify the needs of the team , and ensures the Medical Affairs outstanding deliverables.. Prepare the company for future launches and growth, whether organic or inorganic.

Lead the Medical Affairs

Lead Patient Advocacy

Lead Patient Support Program and Patient Diagnosis Program

Lead RWE and HTA

 NC FARMA São Paulo, Brazil                                                                                                 Mar´20  - May‘22

Medical Director of Holding NC Farma

Lead company's medical-scientific area, being one of the strategic drivers for the business in partnership and actively collaborating with the strategic product marketing plan of all the companies in the Group NC Farma

and ensuring compliance; Identify and promote strategic partnerships with influencers, key scientific and technical decision makers to generate new sources of value for the patient, through, but not exclusively generating and strengthening the relationship with the national and international scientific medical community; Ensure the ideal alignment between medical activities and the priorities of the Multifunctional Therapeutic Teams (CVT) and other internal teams. Ensure communication and alignment with the leaders of each cross-functional team; Collaborate with potential launches by the Licensing & Portfolio areas such as Neuroscience, Cardiometabolic, Woman Health, Pain & Inflammation, Pediatrician, Infectiology, Rare Diseases, among others.   Besides, contribute through product evaluation, rational development of incremental innovation products (new associations); Collaborate with the regulatory area in the evaluation of dossiers, technical evaluation of new partnerships. Support the legal area by issuing technical opinions on processes related to the group's companies; Be a driver in the creation of two-way relationships with stakeholders, both internal and external, to generate value for the business / company and patients; Prepare the company for future launches and growth, whether organic or inorganic.

Lead the Department of Portfolio and Innovation of all companies of the Group NC Farma in all aspects related to ideation, financial viability, clinical development strategy, marketing positioning plan. Ensuring alignment between strategy and funded projects in the innovation pipeline; Optimizing resource loading for priority projects to maximum value creation; Exploring alternative scenarios to optimize investment within and across opportunity areas; Establishing clear project priorities for maximum development throughput; Ensuring appropriate balance of projects by innovation type, strategy and risk profile

Lead the Department of Pharmacovigilance of all companies of the Group NC Farma in all aspects related to production on time and with the quality of reports and their derivatives related to the monitoring of adverse events (product surveillance / drug safety program) to meet the derived demands but not being restricted a: Regulatory, Legal, Business Development, Ministry of Health. Also, responsible for the FMV contracts with all international e national partnership.  

Lead the Clinical Research area in its aspects related to the strategic service of all the companies of the Group NC Farma, from ideation, clinical development plan, internal and external approval to the operationalization and finalization of Clinical Research projects, in any of the research phases, within the predetermined deadlines seeking excellence in quality and adding value to the business including development and Clinical Research of aesthetics products.

UCB Inc. São Paulo, Brazil                                                                                                            2015  - Dec `19                                                                                                    

UCB Commercial Director of Immunology Franchise and                                                       2018  - Dec `19

Commercial Director of Bone Franchise

Research market access, disease awareness, address unmet needs of healthcare professionals, patients, and payers, and design team to launch new bone builder antibody Romosuzumab (Evenity®) in partnership with Amgen as Brazil territory commercial lead. Oversee P&L of Immunology and Bone Units. Ensure regulatory, marketing, and sales strategies align with global positioning. Led UCB Brazil Sustainability Project to be aligned with global strategic plan based on expand and accelerate for the next 3 yrs. Implemented multi-functional project-based collaborations for increased revenues and profitability.

• Established Bone Patient Value Unit while head of Immunology Patient Value Unit.

• Negotiated 12-month contract with fed. government (MoH) with 40%  of growth in patient population.

• Anticipated, in 2019, 6 months the annual contract negotiation with MoH  

• Increased more than 40% the ≠ of patients been benefiting with Cimzia® in the last 10 months

• Achieved 36% vs BDG`19 in YTD Nov`19 been 6% over BDG in Private Market and 52% over BDG in Public Market.

• To YEL`19 is expected to achieve 33% over full BDG`19  

• Related with Access had already approved Cimzia prioritization protocol in the singular Unimeds in some states around Brazil

• Cimzia was incorporated by CONITEC / SUS for Psoriatic arthritis indication

• Finalized the PsO indication protocol to be submitted to CONITEC in Q4T`2019 yet.

• Reduced burden of disease with some innovative initiatives including podcasts by doctors to prolong interaction with patients beyond consultation by identifying patient breakpoints & the 1st Brazilian Virtual Patient Congress achieving more than 2.000 active participants and more then 1MM of visualization

• Delivered short, medium to long-term profitability by defining commercial strategy for private and public sectors on gross and net margin targets.

• Secured federal public reimbursement of main asset in Crohn’s Disease and Ankylosing Spondylitis by collaborating with federal health authorities and internal network.

• Saw 97% multi-cultural team sustainable engagement, 10 points higher than high-performance companies’ norm and 12 points higher than company overall.

• Challenged headquarters product launch decisions after further analysis showed positive reimbursement outcomes from health authorities, so more patients benefited from products.

• Challenged the team to design, evaluate and implement different models to launch and / or continue to growth in the market offering the best value package (product and services) to stakeholders

• Represent UCB in an important Institutional strategic meeting with Minister of Health of Brazil, CONITEC leaders to reinforce the sustainable patient access to UCB solutions  

• Ensured 100% alignment and compliance with local and UCB global compliance standard

UCB, São Paulo, Brazil ​          ​​​​          ​​​                     2015  –     2018

Immunology Medical Affairs Director​​​​​​

• Developed and Led an outstanding Immunology MSL team to launch for KOL and Raising stars the 5 Cimzia® indications as Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthrosis, Psoriasis and Chron Disease, developing advocates and supporting sales and access team.

• Mapped patient journey identifying the breakpoints and unmet needs to design and propose solutions related with education through standalone meetings, workshops and multichannel P2P, which triggered deeper communication among physicians with different backgrounds , ultimately adding value to deeply improve cumbersome patient journeys.  

• Develop a Pilot Remote MSL project using Multichannel other than F2F for 12 months, that was then enlarged and implement in large scale across the country with positive feedback from customers measured by the number of unsolicited requests increasing and average of 15% each quarter.

• Assessed different channels to increase Cimzia® knowledge and differentiation among specialists and generate Cimzia® experience and confidence creating value to our customers.

• Led to build a strong Culture of High-Performance Organization & Patient Centricity.

• Engaged with KOL and Medical Societies to improve the time of auto-immune diagnoses and referral to an effective therapy.

• Conducted actively strategic discussions related with Key accounts plan of action.

• Designed and implemented the Patient Value Network bringing patients and others stakeholders to the co-development of valuable solutions to benefit patients beyond the drug that in the end of the journey the patient elect UCB as the preferred biological company.

•  

• Developed and implemented strategies to communicate and generate Cimzia® protocols standardization and prioritization to the public (MoH) and private (HMOs) payers.

• Led Immunology MSLs team to be ready to participate and contribute actively in the different projects and processes to deliver agility and efficiency improving Cimzia® results.

• Led and provided coach and mentoring to the team setting goals and targets properly supporting them in how to develop individual skills.

Leadership Development Programme, UCB In Company course supported by  Linkage inc, 2018/2019

Master of Business Administration (MBA), FIA, Fundação Instituto de Administração, SP, 2005/2006

Post-Graduation in Marketing , ESPM, Escola Superior de Propaganda e Marketing , SP, 1999/2001

Post-Graduation in Infectiology, EPM, Escola Paulista de Medicina, SP, 1990/1991

Post-Graduation in Pediatrician , Hospital Darcy Vargas, SP, 1988/1990

Doctor in Medicine (MD), Universidade Federal de Juiz de Fora , MG, 1981/1987